Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for healthcare industry professionals · Friday, April 10, 2020 · 514,291,615 Articles · 3+ Million Readers

Myriad Genetics Inc. Therapeutic and Drug Pipeline Review H2



Global Myriad Genetics Inc. Drugs and Companies Pipeline Review H2 2017

PUNE, INDIA, February 3, 2017 / -- Summary
Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that are designed to analyze genes, their expression levels and corresponding proteins to assess a person risk for developing disease later in life, accurately diagnose disease and determine a patient’s likelihood of responding to a particular drug. It also provides an array of pharmaceutical and clinical services. Myriad markets its products through its own sales force in Europe and Canada and through distributor agreements in Latin American, Middle Eastern, Asian and African countries. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, the Netherlands and Italy. Myriad is headquartered in Salt Lake City, Utah, the US.


This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Myriad Genetics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Table of Content: Key Points
Table of Contents 2
List of Tables 5
List of Figures 8
Myriad Genetics Inc Company Overview 9
Myriad Genetics Inc Company Snapshot 9
Myriad Genetics Inc Pipeline Products and Clinical Trials Overview 10
Myriad Genetics Inc – Pipeline Analysis Overview 13
Business Description 13
Key Facts 14
Myriad Genetics Inc - Major Products and Services 15
Myriad Genetics Inc Pipeline Products by Development Stage 16
Myriad Genetics Inc Clinical Trials by Trial Status 19
Myriad Genetics Inc Pipeline Products Overview 21
BRACAnalysis CDx - Breast Cancer 21
BRACAnalysis CDx - Breast Cancer Product Overview 21
BRACAnalysis CDx - Ovarian Cancer 22
BRACAnalysis CDx - Ovarian Cancer Product Overview 22
BRACAnalysis CDx - Pancreatic Cancer 23
BRACAnalysis CDx - Pancreatic Cancer Product Overview 23
ChemoPredict Test 24
ChemoPredict Test Product Overview 24
Diagnostic Assay - Lung Cancer 25
Diagnostic Assay - Lung Cancer Product Overview 25
Diagnostic Assay - HER2+/TNBC-Breast Cancer 26


Get in touch:

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release